Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
Status:
Completed
Trial end date:
2020-12-16
Target enrollment:
Participant gender:
Summary
This is Phase 1/2 study of avadomide (CC-122) in combination with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, for
first-line treatment of patients with Diffuse B-Cell Large B-Cell Lymphoma (DLBCL) that has
poor risk factors. Approximately 40% of patients diagnosed with DLBCL are not cured with
R-CHOP alone and would need additional treatment for DLBCL in the future. The addition of the
experimental drug avadomide (CC-122) with R-CHOP could help in controlling DLBCL in this
patient population.